Trade C4 Therapeutics, Inc. - CCCC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.07 |
| Open | 1.13 |
| 1-Year Change | -83.43% |
| Day's Range | 1.13 - 1.25 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2025 | 1.21 | 0.14 | 13.08% | 1.07 | 1.26 | 1.07 |
| Apr 16, 2025 | 1.07 | -0.08 | -6.96% | 1.15 | 1.17 | 1.06 |
| Apr 15, 2025 | 1.16 | -0.03 | -2.52% | 1.19 | 1.28 | 1.14 |
| Apr 14, 2025 | 1.18 | -0.04 | -3.28% | 1.22 | 1.24 | 1.14 |
| Apr 11, 2025 | 1.19 | -0.01 | -0.83% | 1.20 | 1.22 | 1.14 |
| Apr 10, 2025 | 1.18 | -0.08 | -6.35% | 1.26 | 1.26 | 1.14 |
| Apr 9, 2025 | 1.25 | 0.12 | 10.62% | 1.13 | 1.30 | 1.05 |
| Apr 8, 2025 | 1.17 | -0.22 | -15.83% | 1.39 | 1.39 | 1.17 |
| Apr 7, 2025 | 1.29 | 0.09 | 7.50% | 1.20 | 1.30 | 1.14 |
| Apr 4, 2025 | 1.26 | -0.07 | -5.26% | 1.33 | 1.33 | 1.24 |
| Apr 3, 2025 | 1.34 | -0.05 | -3.60% | 1.39 | 1.41 | 1.33 |
| Apr 2, 2025 | 1.48 | 0.11 | 8.03% | 1.37 | 1.53 | 1.37 |
| Apr 1, 2025 | 1.40 | -0.15 | -9.68% | 1.55 | 1.56 | 1.40 |
| Mar 31, 2025 | 1.56 | -0.12 | -7.14% | 1.68 | 1.68 | 1.55 |
| Mar 28, 2025 | 1.71 | -0.07 | -3.93% | 1.78 | 1.79 | 1.71 |
| Mar 27, 2025 | 1.80 | -0.04 | -2.17% | 1.84 | 1.84 | 1.77 |
| Mar 26, 2025 | 1.82 | -0.29 | -13.74% | 2.11 | 2.11 | 1.76 |
| Mar 25, 2025 | 2.14 | -0.02 | -0.93% | 2.16 | 2.21 | 2.03 |
| Mar 24, 2025 | 2.18 | 0.05 | 2.35% | 2.13 | 2.25 | 2.08 |
| Mar 21, 2025 | 2.07 | -0.05 | -2.36% | 2.12 | 2.14 | 2.05 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
C4 Therapeutics, Inc. Company profile
About C4 Therapeutics Inc
C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, C4 Therapeutics Inc revenues increased 38% to $45.8M. Net loss increased 26% to $83.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $2.5M to $14M (expense), Research and development - Balancing val increase of 12% to $87.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
490 Arsenal Way
Suite 120
WATERTOWN
MASSACHUSETTS 02472
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com